Erturan Zayre, Uzun Meltem
Istanbul University, Istanbul Faculty of Medicine, Department of Microbiology and Clinical Microbiology, 34390 Capa, Istanbul, Turkey.
Int J Antimicrob Agents. 2005 Jul;26(1):78-80. doi: 10.1016/j.ijantimicag.2005.03.006.
Information in the literature regarding the activity of linezolid against multidrug-resistant (MDR) Mycobacterium tuberculosis strains is scarce. We therefore tested the in vitro activity of this drug against 39 MDR M. tuberculosis strains isolated from clinical specimens using the Bactec 460 TB system. All strains were inhibited by < or = 8 mg/L (minimum inhibitory concentration (MIC); MIC50 = 4 mg/L, MIC90 = 8 mg/L). Although the MIC values are higher than in other studies, based on proposed breakpoints all strains were found to be susceptible to linezolid. Further investigations to prove its usefulness in the treatment of MDR tuberculosis should be carried out.
关于利奈唑胺对耐多药（MDR）结核分枝杆菌菌株活性的文献资料很少。因此，我们使用Bactec 460 TB系统测试了该药物对从临床标本中分离出的39株MDR结核分枝杆菌菌株的体外活性。所有菌株均被≤8mg/L抑制（最低抑菌浓度（MIC）；MIC50 = 4mg/L，MIC90 = 8mg/L）。尽管MIC值高于其他研究，但根据建议的断点，发现所有菌株对利奈唑胺敏感。应进行进一步研究以证明其在耐多药结核病治疗中的有效性。
